These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31529406)

  • 1. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
    Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
    Munafo A; Priestley A; Nestorov I; Visich J; Rogge M
    Eur J Clin Pharmacol; 2007 Jul; 63(7):647-56. PubMed ID: 17473917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.
    Nestorov I; Munafo A; Papasouliotis O; Visich J
    J Clin Pharmacol; 2008 Apr; 48(4):406-17. PubMed ID: 18303125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
    Tak PP; Thurlings RM; Rossier C; Nestorov I; Dimic A; Mircetic V; Rischmueller M; Nasonov E; Shmidt E; Emery P; Munafo A
    Arthritis Rheum; 2008 Jan; 58(1):61-72. PubMed ID: 18163485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.
    Chen X; Hou Y; Jiang J; Zhao Q; Zhong W; Wang W; Yao X; Li L; Fang J; Zhang F; Hu P
    Clin Pharmacokinet; 2014 Nov; 53(11):1033-44. PubMed ID: 25179916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
    Dall'Era M; Chakravarty E; Wallace D; Genovese M; Weisman M; Kavanaugh A; Kalunian K; Dhar P; Vincent E; Pena-Rossi C; Wofsy D
    Arthritis Rheum; 2007 Dec; 56(12):4142-50. PubMed ID: 18050206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
    Ikushima I; Jensen L; Flint A; Nishida T; Zacho J; Irie S
    Adv Ther; 2018 Apr; 35(4):531-544. PubMed ID: 29536338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.
    Pena-Rossi C; Nasonov E; Stanislav M; Yakusevich V; Ershova O; Lomareva N; Saunders H; Hill J; Nestorov I
    Lupus; 2009 May; 18(6):547-55. PubMed ID: 19395457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus.
    Nestorov I; Papasouliotis O; Pena Rossi C; Munafo A
    J Pharm Sci; 2010 Jan; 99(1):524-38. PubMed ID: 19743503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
    Stohl W; Merrill JT; Looney RJ; Buyon J; Wallace DJ; Weisman MH; Ginzler EM; Cooke B; Holloway D; Kaliyaperumal A; Kuchimanchi KR; Cheah TC; Rasmussen E; Ferbas J; Belouski SS; Tsuji W; Zack DJ
    Arthritis Res Ther; 2015 Aug; 17(1):215. PubMed ID: 26290435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.
    Zhao Q; Brett M; Van Osselaer N; Huang F; Raoult A; Van Peer A; Verhaeghe T; Hust R
    J Clin Pharmacol; 2002 Sep; 42(9):1002-10. PubMed ID: 12211216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept.
    Carbonatto M; Yu P; Bertolino M; Vigna E; Steidler S; Fava L; Daghero C; Roattino B; Onidi M; Ardizzone M; Peano S; Visich J; Janszen D; Dillon S; Ponce R
    Toxicol Sci; 2008 Sep; 105(1):200-10. PubMed ID: 18522929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants.
    Li X; Haranaka M; Li H; Liu P; Chen H; Klein S; Reif S; Francke K; Friedrich C; Okumura K
    Clin Pharmacokinet; 2024 Jun; 63(6):901-915. PubMed ID: 38907175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.
    Thomsen MS; Chassard D; Evène E; Nielsen KK; Jørgensen M
    J Clin Pharmacol; 2003 Jan; 43(1):23-8. PubMed ID: 12520624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.
    Ginzler EM; Wax S; Rajeswaran A; Copt S; Hillson J; Ramos E; Singer NG
    Arthritis Res Ther; 2012 Feb; 14(1):R33. PubMed ID: 22325903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma.
    Ansell SM; Witzig TE; Inwards DJ; Porrata LF; Ythier A; Ferrande L; Nestorov I; Devries T; Dillon SR; Hausman D; Novak AJ
    Clin Cancer Res; 2008 Feb; 14(4):1105-10. PubMed ID: 18281543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
    Vutikullird AB; Gillespie M; Song S; Steinfeld J
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.